A - Human Necessities – 61 – K
Patent
A - Human Necessities
61
K
A61K 31/4545 (2006.01) A61K 31/138 (2006.01) A61K 31/4196 (2006.01) A61K 31/565 (2006.01) A61K 31/5685 (2006.01) A61K 45/06 (2006.01)
Patent
CA 2544421
A method of treating breast cancer is disclosed. The method comprises administering an FTI, at least one antihormonal agent (e.g., an aromatase inhibitor, an antiestrogen, and an LHRH analogue), optional chemotherapeutic agents (e.g., Trastuzumab), and optional radiation. For example, the treatment of breast cancer using the FTI and Anastrozole is disclosed. Also disclosed is a method of treating breast cancer using the FTI Anastrozole and Fulvestrant. Also disclosed are pharmaceutical compositions comprising an FTI, at least one antihormonal agent and a pharmaceutically acceptable carrier; and compositions comprising an FTI, at least one antihormonal agent, at least one chemotherapeutic agent, and a pharmaceutically acceptable carrier; and compositions comprising an FTI, at least one chemotherapeutic agent, and a pharmaceutically acceptable carrier.
L'invention porte sur un procédé de traitement du cancer du sein, selon lequel on administre un inhibiteur de la farnesyl transférase (FTI), au moins un agent antihormonal (p.ex., un inhibiteur de l'aromatase, un antioestrogène, et un analogue de la LHRH), des agents chimiothérapeutiques facultatifs (p.ex., du Trastuzumab), et des rayonnements facultatifs. L'invention concerne, par exemple, un traitement du cancer du sein par un FTI et de l'anastrozole. L'invention se rapporte également à un procédé qui permet de traiter le cancer du sein avec un FTI, de l'anastrozole et du fulvestrant. L'invention concerne aussi des compositions pharmaceutiques comprenant un FTI, au moins un agent antihormonal et un excipient pharmaceutiquement acceptable ; et des compositions comprenant un FTI, au moins un agent antihormonal, au moins un agent chimiothérapeutique et un excipient pharmaceutiquement acceptable ; et des compositions comprenant un FTI, au moins un agent chimiothérapeutique et un excipient pharmaceutiquement acceptable.
Alland Leila
Bishop Walter Robert
Kirschmeier Paul
Long Brian
Tendler Craig
Ogilvy Renault Llp/s.e.n.c.r.l.,s.r.l.
Schering Corporation
LandOfFree
Combination of a farnesyl transferase inhibitor with an... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Combination of a farnesyl transferase inhibitor with an..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Combination of a farnesyl transferase inhibitor with an... will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1386117